# Bayer CropScience share price today (Bayer CropScience Ltd, NSE: BAYERCROP) > Bayer CropScience share price today: ₹3,351.80 at the NSE close on 18 November 2026, down 26.2% in a year. Bayer CropScience (NSE: BAYERCROP) is worth ₹15,064 crore, trades at a P/E of 20.2 and has closed between ₹3,256.70 and ₹4,898.20 over the past 52 weeks. > Bayer CropScience Ltd's earnings have grown faster than its share price. Earnings per share grew +21.3% in a year while the price moved −26.2%. BAYERCROP · Pesticides/Agrochemicals · data as of 18 November 2026. Page: https://www.sectoralpha.in/stocks/bayer-cropscience-ltd Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms ## Key numbers - Business trend: Getting better, from the last 12 quarters - Price: ₹3,351.80 (−26.2% in a year) - P/E: 20.2× (lower than 100% of the last 10 years) - Revenue (Sep 2026): ₹1,251 Cr (−19.4% on a year ago) - Profit (Sep 2026): ₹166 Cr (+8.5% on a year ago) - Operating margin: 17.4% (+4.2 points on a year ago) - ROCE: 29%, FY26 - ROIC: 29.4%, against a 12.0% cost of capital: +17.4 points The main question: yearly earnings per share moved +21.3% while the share price moved −26.2%. ## What is the Bayer CropScience share price today? Bayer CropScience Ltd's share price was ₹3,351.80 at the close on 18 November 2026. It has been falling for 59 weeks. That is 18.8% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹3,257 and ₹4,898, and at that close it sat 6% of the way up from that low. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 32 weeks running. Over the last 11 years the share price moved −5% while the NIFTY 500 moved +279%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 22 May 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Bayer CropScience this quarter? Two changes stood out: profit up on a year earlier for 7 quarters in a row and operating margin up 4 points on a year earlier. 1. Profit up on a year earlier for 7 quarters in a row In the September 2026 quarter profit was ₹166 crore, +8.5% on a year earlier. 2. Operating margin up 4 points on a year earlier 17% in the September 2026 quarter, from 13%. ## What dividend does Bayer CropScience pay? Bayer CropScience paid ₹150 a share in regular dividends in the 12 months to 18 November 2026 (2 payments), a yield of 4.48% at the ₹3,351.80 close on 18 November 2026. The last was an interim dividend of ₹90 a share, ex-date 12 November 2026. ### Bayer CropScience dividends since 1 April 2021 | Ex-date | Dividend per share | Type | Record date | | --- | --- | --- | --- | | 12 Nov 2026 | ₹90 | Interim | same day | | 5 Aug 2026 | ₹60 | Dividend | same day | | 14 Nov 2025 | ₹90 | Interim | same day | | 7 Aug 2025 | ₹35 | Dividend | same day | | 28 Nov 2024 | ₹90 | Interim | same day | | 1 Aug 2024 | ₹35 | Dividend | n/a | | 16 Nov 2023 | ₹105 | Interim | same day | | 4 Aug 2023 | ₹30 | Dividend | n/a | | 17 Nov 2022 | ₹100 | Interim | 19 Nov 2022 | | 4 Aug 2022 | ₹25 | Dividend | n/a | | 11 Nov 2021 | ₹125 | Special | 13 Nov 2021 | | 27 Jul 2021 | ₹25 | Dividend | n/a | Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. 5 of 5 Of the last 5 financial years, years with an NSE dividend record Yes. Bayer CropScience Ltd paid out 98% of its profit as dividends in FY26, and it paid a dividend in each of its last 14 reported years. (From the NSE corporate-actions record, read 18 November 2026.) ## What are Bayer CropScience's latest quarterly results? For July to September 2026 (the quarter ended 30 September 2026), Bayer CropScience reported revenue of ₹1,251 crore, down 19.4% from ₹1,553 crore a year earlier, and a profit of ₹166 crore, up 8.5% from ₹153 crore. ### Bayer CropScience results: July to September 2026 against a year earlier | Measure | July to September 2026 | July to September 2025 | Change | | --- | --- | --- | --- | | Revenue | ₹1,251 crore | ₹1,553 crore | −19.4% | | Profit | ₹166 crore | ₹153 crore | +8.5% | | Earnings per share | ₹36.98 | ₹33.98 | +8.8% | | Operating margin | 17.4% | 13.2% | +4.2 points | The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). (From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.) ## What is the Bayer CropScience share price history? Bayer CropScience closed at ₹3,351.80 on 18 November 2026, down 26.2% from ₹4,544.60 a year earlier (21 November 2025) and down 29.3% over five years. Its highest weekly close since March 2016 was ₹6,874.55 on 2 August 2024. ### Bayer CropScience share price: then and now | When | Close | Change to 18 Nov 2026 | | --- | --- | --- | | 1 week ago · 11 Nov 2026 | ₹3,603.80 | −7.0% | | 1 month ago · 19 Oct 2026 | ₹3,548.20 | −5.5% | | 6 months ago · 15 May 2026 | ₹4,349.80 | −22.9% | | 1 year ago · 21 Nov 2025 | ₹4,544.60 | −26.2% | | 3 years ago · 17 Nov 2023 | ₹5,371.00 | −37.6% | | 5 years ago · 18 Nov 2021 | ₹4,743.00 | −29.3% | | 10 years ago · 18 Nov 2016 | ₹3,916.30 | −14.4% | | Earliest weekly close in our records · 11 Mar 2016 | ₹3,542.70 | −5.4% | | Highest weekly close since March 2016 · 2 Aug 2024 | ₹6,874.55 | −51.2% | | Lowest weekly close since March 2016 · 2 Aug 2019 | ₹2,998.45 | +11.8% | | 52-week high (weekly close) · 17 Apr 2026 | ₹4,898.20 | −31.6% | | 52-week low (weekly close) · 30 Oct 2026 | ₹3,256.70 | +2.9% | Weekly closing prices. Each change is the move from that price to the 18 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (563 weekly closes from 11 March 2016 to 18 November 2026.) ## What is the latest news on Bayer CropScience? 18 Nov 2026: Bayer CropScience closed at ₹3,351.80, down 7.0% on the week and down 5.5% on the month. 12 Nov 2026: ex-date for an interim dividend of ₹90 a share. ### Earlier - Results for July to September 2026: Revenue down 19.4% and profit up 8.5% on a year earlier. - 5 Aug 2026: ex-date for a dividend of ₹60 a share. ## What to watch in Bayer CropScience's next results? When Bayer CropScience reports October to December 2026, these are the 3 checks that show whether the story is still on course. First: Revenue against the same quarter a year earlier. - Revenue against the same quarter a year earlier. In the Sep 2026 quarter, revenue was −19.4% on a year earlier, and the last four quarters averaged −3.4%. - Whether the operating margin stays near 17.4%. It is 4.2 percentage points higher than four quarters earlier. - Net profit against the same quarter a year earlier. In the Sep 2026 quarter, profit was +8.5% on a year earlier. It has grown on a year earlier for 7 quarters in a row. ## Which stock lists is Bayer CropScience on? Bayer CropScience is on 2 of our India lists: Dividend stocks and Small & mid cap stocks. - [Dividend stocks Regular dividend yield (%): 4.5](https://www.sectoralpha.in/dividend-stocks-india) - [Small & mid cap stocks Size rank in India: 450](https://www.sectoralpha.in/small-cap-stocks-india) ## Is Bayer CropScience profitable? Bayer CropScience Ltd earned ₹166 Cr of net profit in the Sep 2026 quarter, +8.5% on the same quarter a year earlier. That is the 7th quarter in a row of profit growth. Full-year FY26 profit was ₹689 Cr. Over 10 years profit has grown 8.1% a year on average. The same quarter a year earlier earned ₹153 Cr. The Sep 2026 quarter's profit is 13.3% of that quarter's revenue. For the full year, FY26 profit was ₹689 Cr (+21.3% on the year before). Why profit moved: revenue changed −19.4% on a year earlier and the margin moved +4.2 percentage points. Most of the change came from keeping more of each sale. On average over the last four quarters, profit changed +54.9% and revenue −3.4%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit. ## How much revenue does Bayer CropScience make, and is it growing? Bayer CropScience Ltd reported ₹1,251 Cr of revenue in the Sep 2026 quarter, −19.4% on the same quarter a year earlier. Over 10 years it has grown 7.4% a year on average. The last full year, FY26, came in at ₹5,675 Cr. The last four reported quarters add to ₹5,293 Cr. FY26 revenue was ₹5,675 Cr, +3.7% on the year before. Recent pace: the last four quarters grew −3.4% on average, against 7.4% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew −5.0%, against +1.7% a year over the last 8 quarters (rolling over); profit over the last 12 months grew +22.5%, against +13.5% a year (accelerating). ## How much of every ₹100 of sales does Bayer CropScience keep? Bayer CropScience Ltd's operating margin was 17.4% in the Sep 2026 quarter, 4.2 percentage points higher than the same quarter a year ago. Across 14 years it has been between 4.8% and 20.1%. The latest quarter is within that range. Why the margin moved: operating margin changed +4.2 percentage points on the year while gross margin changed +8.7 points. So the gain came mostly from the gross margin, which means input costs and prices charged. ## Is Bayer CropScience's profit turning into cash? Over the last 3 years, 115% of Bayer CropScience Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹1,078 Cr of operating cash against ₹689 Cr of profit. After ₹40.0 Cr of spending on assets, ₹1,039 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 115% of profit came in as cash: the cash cycle got 44 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. What to look at next: no single use of cash stands out. The next section checks both the cash tied up in daily operations and the spending on assets. ## Where does Bayer CropScience's cash go? Bayer CropScience Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 193 days in FY26, up from 149 days in FY21. It spent ₹112 Cr on assets over the last 3 years. Customers take 72 days to pay, and stock sits for 289 days on average. At FY26 sales of ₹5,675 Cr, each day of that cycle ties up about ₹15.5 Cr, so roughly ₹3,001 Cr is tied up in the business at any time. FY26: customers took 72 days to pay and stock sat for 289 days, about 9.5 months of sales sitting as stock, for a full cycle of 193 days, longer than FY21's 149. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 289 days. Customers pay about 72 days after that. Suppliers are paid at 167 days. Together that makes the 193-day cycle. Spending on assets: ₹112 Cr over the last 3 years, against ₹253 Cr of depreciation (the yearly wear and tear on existing assets). So it is spending about what it takes to replace what wears out, or less. Work still in progress is ₹127 Cr (FY26): assets paid for that are not earning yet. In short: neither the daily cycle nor new spending is soaking up the cash, so the picture is fairly clean. ## What is Bayer CropScience's P/E ratio, and how does it compare with its own history? Bayer CropScience Ltd's P/E is 20.2×, about the lowest it has ever been. Its usual P/E (the middle reading) is 40.9×, over 10 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved +21.3% while the price moved −26.2%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 5 years the price moved −6.7% a year; about +12.1% a year came from earnings growth and about −18.8 percentage points from the multiple (the market paying less); over 10 years the price moved −1.5% a year; about +5.6% a year came from earnings growth and about −7.1 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Bayer CropScience business getting better or worse? Bayer CropScience Ltd's business is getting better. Profit growth was −21.3% 6 quarters ago and has recovered to +22.5%, with ROCE rising at 28.9% (four quarters to Sep 2026). This is based on 12 quarters of 4 measures. Why it matters: a lasting rise from a low is what this page is built to show. ## How much does Bayer CropScience earn on its capital? Bayer CropScience Ltd earned a ROCE of 29% in FY26. That is up from a low of 20% in Dec 2006. Its return on capital used (ROIC) is 17.4 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 12.1% net margin and 1.00× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 12.1% net margin × 1.00× asset turnover × 1.92× leverage (assets divided by equity) ≈ 23.2% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 29.4% − 12.0% = +17.4 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. A gap this wide means each rupee put back into the business creates more than a rupee of value. The 29.4% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 34.8%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Bayer CropScience have too much debt? Bayer CropScience Ltd has total debt of ₹70.0 Cr against shareholder equity of ₹3,184 Cr as of Sep 2026, so its debt is 0.02× its equity, which is very little. Year by year, that ratio went from 0.03 in FY22 to 0.03 in FY26. So the returns on this page come from the business, not from borrowed money. ## What is the Bayer CropScience shareholding pattern? No group of Bayer CropScience Ltd's owners changed its stake by a full percentage point over the last two years. Domestic institutions moved −0.6 points over the same period, to 11.5%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Foreign institutions: +0.7 points over 8 quarters, to 4.0%; Domestic institutions: −0.6 points over 8 quarters, to 11.5%; Promoters: +0.0 points over 8 quarters, to 71.4%. ## How far is Bayer CropScience from balance-sheet trouble? For Bayer CropScience Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Bayer CropScience rank in its industry? 63.0 out of 100, rank 4 of 25 in Pesticides/Agrochemicals, with 85% of the evidence available. Bayer CropScience Ltd scores 63.0 out of 100 against the 25 companies it is compared with in Pesticides/Agrochemicals, ranking 4. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 24.5 + 19.3 + 10.6 + 8.6 = 63. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Bayer CropScience compared with? Bayer CropScience ranks 4 of 25 Pesticides/Agrochemicals companies on the 4-Factor Sector Score, with 63.0 out of 100. 1. [Titan Biotech Ltd](https://www.sectoralpha.in/stocks/titan-biotech-ltd) breaking out · Most evidence points up · 87% evidence 76.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.3/35 · Revenue 31.8% · Profit 38.7% · Operating margin change 3 points · 95% evidence Capital efficiency 21.3/25 · ROCE 22.8% (year to Mar 2026) · Operating margin 19.7% · 95% evidence Valuation 5.4/20 · P/E 55.2× · PEG n/a · 50% evidence Relative strength 18.6/20 · Strength vs its industry (price vs its 52-week average, weekly) 44.3% · Strength vs NIFTY 500 (same reading) 21.3% · 1 year 177.2% · 100% evidence · 4 of 12 weeks ahead Exact sum: 31.3 + 21.3 + 5.4 + 18.6 = 76.6 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Sharda Cropchem Ltd](https://www.sectoralpha.in/stocks/sharda-cropchem-ltd) SHARDACROP · basing · Most evidence points up · 100% evidence 66.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.2/35 · Revenue 17.3% · Profit 42.5% · Operating margin change 2 points · 100% evidence Capital efficiency 19.6/25 · ROCE 30.2% (year to Mar 2026) · Operating margin 15.6% · 100% evidence Valuation 11.5/20 · P/E 9.8× · PEG 2.26 · 100% evidence Relative strength 7.6/20 · Strength vs its industry (price vs its 52-week average, weekly) -5.2% · Strength vs NIFTY 500 (same reading) -21.1% · 1 year -12.6% · 100% evidence · 0 of 12 weeks ahead Exact sum: 28.2 + 19.6 + 11.5 + 7.6 = 66.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [Jubilant Ingrevia Ltd](https://www.sectoralpha.in/stocks/jubilant-ingrevia-ltd) JUBLINGREA · quiet · Most evidence points up · 93% evidence 65.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 27.4/35 · Revenue 15.4% · Profit 21.9% · Operating margin change 3 points · 100% evidence Capital efficiency 13.8/25 · ROCE 11.4% (year to Mar 2026) · Operating margin 15.2% · 100% evidence Valuation 12.9/20 · P/E 26.7× · PEG 1.16 · 65% evidence Relative strength 11.2/20 · Strength vs its industry (price vs its 52-week average, weekly) 3.8% · Strength vs NIFTY 500 (same reading) -13.5% · 1 year -18.5% · 100% evidence · 2 of 12 weeks ahead Exact sum: 27.4 + 13.8 + 12.9 + 11.2 = 65.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. Bayer CropScience Ltd this page BAYERCROP · quiet · Evidence leans up · 85% evidence 63.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.5/35 · Revenue -5% · Profit 22.5% · Operating margin change 4 points · 100% evidence Capital efficiency 19.3/25 · ROCE 29.1% (year to Mar 2026) · Operating margin 17.4% · 100% evidence Valuation 10.6/20 · P/E 20.2× · PEG 2.22 · 100% evidence Relative strength 8.6/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) -22.1% · 1 year -26.2% · 25% evidence · 0 of 12 weeks ahead Exact sum: 24.5 + 19.3 + 10.6 + 8.6 = 63 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Dhanuka Agritech Ltd](https://www.sectoralpha.in/stocks/dhanuka-agritech-ltd) DHANUKA · quiet · Evidence leans up · 100% evidence 54.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 10.0/35 · Revenue 0% · Profit 0.7% · Operating margin change 0 points · 100% evidence Capital efficiency 19.8/25 · ROCE 25.9% (year to Mar 2026) · Operating margin 23.3% · 100% evidence Valuation 11.4/20 · P/E 14.8× · PEG 2.07 · 100% evidence Relative strength 13.5/20 · Strength vs its industry (price vs its 52-week average, weekly) 0.8% · Strength vs NIFTY 500 (same reading) -16.1% · 1 year -23.7% · 100% evidence · 0 of 12 weeks ahead Exact sum: 10 + 19.8 + 11.4 + 13.5 = 54.7 · What this means: Relative strength against the index is -16.1%, and revenue and profit growth are weak. 6. [Advance Agrolife Ltd](https://www.sectoralpha.in/stocks/advance-agrolife-ltd) ADVANCE · losing its lead · Evidence leans up · 68% evidence 54.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.0/35 · Revenue 49.4% · Profit 55.2% · Operating margin change -4 points · 100% evidence Capital efficiency 13.7/25 · ROCE 19.6% (year to Mar 2026) · Operating margin 7.7% · 100% evidence Valuation 10.1/20 · P/E 17.4× · PEG n/a · 15% evidence Relative strength 11.9/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) 2.3% · 1 year -8.5% · 25% evidence · 10 of 12 weeks ahead Exact sum: 19 + 13.7 + 10.1 + 11.9 = 54.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Punjab Chemicals & Crop Protection Ltd](https://www.sectoralpha.in/stocks/punjab-chemicals-crop-protection-ltd) PUNJABCHEM · quiet · Evidence leans up · 75% evidence 53.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.6/35 · Revenue 14% · Profit 13.2% · Operating margin change -1 points · 100% evidence Capital efficiency 13.2/25 · ROCE 18.6% (year to Mar 2026) · Operating margin 9.2% · 100% evidence Valuation 11.0/20 · P/E 17.9× · PEG n/a · 50% evidence Relative strength 9.2/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) -19% · 1 year -34.1% · 25% evidence · 3 of 12 weeks ahead Exact sum: 19.6 + 13.2 + 11 + 9.2 = 53 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Dharmaj Crop Guard Ltd](https://www.sectoralpha.in/stocks/dharmaj-crop-guard-ltd) DHARMAJ · quiet · Evidence leans up · 75% evidence 52.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 14.5/35 · Revenue 3.8% · Profit 14.3% · Operating margin change -2 points · 100% evidence Capital efficiency 14.7/25 · ROCE 16.8% (year to Mar 2026) · Operating margin 7.2% · 100% evidence Valuation 13.2/20 · P/E 15.1× · PEG n/a · 50% evidence Relative strength 10.0/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) -9.7% · 1 year -0.9% · 25% evidence · 5 of 12 weeks ahead Exact sum: 14.5 + 14.7 + 13.2 + 10 = 52.4 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. 9. [Best Agrolife Ltd](https://www.sectoralpha.in/stocks/best-agrolife-ltd) BESTAGRO · quiet · Evidence leans up · 90% evidence 52.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.7/35 · Revenue -19.6% · Profit 100% · Operating margin change 10 points · 100% evidence Capital efficiency 10.0/25 · ROCE 5.2% (year to Mar 2026) · Operating margin 24.8% · 100% evidence Valuation 11.3/20 · P/E 10.8× · PEG n/a · 50% evidence Relative strength 6.0/20 · Strength vs its industry (price vs its 52-week average, weekly) -4.7% · Strength vs NIFTY 500 (same reading) -20.8% · 1 year -26.5% · 100% evidence · 7 of 12 weeks ahead Exact sum: 24.7 + 10 + 11.3 + 6 = 52 · What this means: Earnings are strong; relative strength in its sector is -4.7% and the one-year return is -26.5%. 10. [Meghmani Organics Ltd](https://www.sectoralpha.in/stocks/meghmani-organics-ltd) MOL · quiet · Evidence leans down · 68% evidence 49.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.9/35 · Revenue -5.2% · Profit 100% · Operating margin change 2 points · 100% evidence Capital efficiency 7.7/25 · ROCE 6.7% (year to Mar 2026) · Operating margin 10.9% · 100% evidence Valuation 10.4/20 · P/E 15.6× · PEG n/a · 15% evidence Relative strength 10.7/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) -2.3% · 1 year -23.9% · 25% evidence · 8 of 12 weeks ahead Exact sum: 20.9 + 7.7 + 10.4 + 10.7 = 49.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [Excel Industries Ltd](https://www.sectoralpha.in/stocks/excel-industries-ltd) EXCELINDUS · losing its lead · Evidence leans down · 68% evidence 49.0 out of 100 Growth Capital Valuation Relative 12. [UPL Ltd](https://www.sectoralpha.in/stocks/upl-ltd) UPL · basing · Evidence leans down · 82% evidence 48.9 out of 100 Growth Capital Valuation Relative 13. [Rallis India Ltd](https://www.sectoralpha.in/stocks/rallis-india-ltd) RALLIS · quiet · Evidence leans down · 85% evidence 47.9 out of 100 Growth Capital Valuation Relative 14. [Shivalik Rasayan Ltd](https://www.sectoralpha.in/stocks/shivalik-rasayan-ltd) SHIVALIK · turning · Evidence leans down · 67% evidence 47.9 out of 100 Growth Capital Valuation Relative 15. [Bhagiradha Chemicals & Industries Ltd](https://www.sectoralpha.in/stocks/bhagiradha-chemicals-industries-ltd) BHAGCHEM · quiet · Evidence leans down · 83% evidence 47.7 out of 100 Growth Capital Valuation Relative 16. [Epigral Ltd](https://www.sectoralpha.in/stocks/epigral-ltd) EPIGRAL · quiet · Evidence leans down · 75% evidence 46.8 out of 100 Growth Capital Valuation Relative 17. [India Pesticides Ltd](https://www.sectoralpha.in/stocks/india-pesticides-ltd) IPL · quiet · Evidence leans down · 75% evidence 46.0 out of 100 Growth Capital Valuation Relative 18. [Sumitomo Chemical India Ltd](https://www.sectoralpha.in/stocks/sumitomo-chemical-india-ltd) SUMICHEM · quiet · Evidence leans down · 85% evidence 43.7 out of 100 Growth Capital Valuation Relative 19. [Insecticides India Ltd](https://www.sectoralpha.in/stocks/insecticides-india-ltd) INSECTICID · quiet · Evidence leans down · 90% evidence 42.8 out of 100 Growth Capital Valuation Relative 20. [Bharat Rasayan Ltd](https://www.sectoralpha.in/stocks/bharat-rasayan-ltd) BHARATRAS · basing · Evidence leans down · 90% evidence 42.4 out of 100 Growth Capital Valuation Relative 21. [GSP Crop Science Ltd](https://www.sectoralpha.in/stocks/gsp-crop-science-ltd) GSPCROP · quiet · Evidence leans down · 63% evidence 39.8 out of 100 Growth Capital Valuation Relative 22. [P I Industries Ltd](https://www.sectoralpha.in/stocks/p-i-industries-ltd) PIIND · quiet · Most evidence points down · 75% evidence 34.5 out of 100 Growth Capital Valuation Relative 23. [NACL Industries Ltd](https://www.sectoralpha.in/stocks/nacl-industries-ltd) NACLIND · basing · Most evidence points down · 90% evidence 32.9 out of 100 Growth Capital Valuation Relative 24. [Heranba Industries Ltd](https://www.sectoralpha.in/stocks/heranba-industries-ltd) HERANBA · quiet · Most evidence points down · 71% evidence 31.9 out of 100 Growth Capital Valuation Relative 25. [Astec Lifesciences Ltd](https://www.sectoralpha.in/stocks/astec-lifesciences-ltd) ASTEC · quiet · Most evidence points down · 71% evidence 31.3 out of 100 Growth Capital Valuation Relative Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. In this ranking every company's P/E uses its own latest official close and its last four filed quarters, the same rule as the top of this page. ROCE here is each company's last full year, as labelled, so it can differ from the four-quarter ROCE above. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pesticides/Agrochemicals](https://www.sectoralpha.in/sectors/pesticides-agrochemicals), all 25 compared on one page. ## Which companies are close to Bayer CropScience in size? Bayer CropScience is the 4th largest of 25 Pesticides/Agrochemicals companies on Sector Alpha by market value (at the 18 November 2026 close). Just above it: UPL, P I Industries and Sumitomo Chemical India. Just below it: Jubilant Ingrevia, Sharda Cropchem and Dhanuka Agritech. ### Pesticides/Agrochemicals companies close in size 1. [UPL Ltd](https://www.sectoralpha.in/stocks/upl-ltd) ₹46,584 crore 2. [P I Industries Ltd](https://www.sectoralpha.in/stocks/p-i-industries-ltd) ₹24,639 crore 3. [Sumitomo Chemical India Ltd](https://www.sectoralpha.in/stocks/sumitomo-chemical-india-ltd) ₹16,684 crore 4. Bayer CropScience Ltd ₹15,064 crore 5. [Jubilant Ingrevia Ltd](https://www.sectoralpha.in/stocks/jubilant-ingrevia-ltd) ₹9,348 crore 6. [Sharda Cropchem Ltd](https://www.sectoralpha.in/stocks/sharda-cropchem-ltd) ₹6,305 crore 7. [Dhanuka Agritech Ltd](https://www.sectoralpha.in/stocks/dhanuka-agritech-ltd) ₹4,173 crore [All 25 Pesticides/Agrochemicals companies, largest first](https://www.sectoralpha.in/sectors/pesticides-agrochemicals#all-companies) ### Companies close in size in other industries 1. [Astrazeneca Pharma India Ltd](https://www.sectoralpha.in/stocks/astrazeneca-pharma-india-ltd) ₹15,109 crore · Pharma - MNC bulk Drugs 2. [Devyani International Ltd](https://www.sectoralpha.in/stocks/devyani-international-ltd) ₹15,107 crore · Quick Service Restaurant - QSR 3. Bayer CropScience Ltd ₹15,064 crore 4. [Swan Defence and Heavy Industries Ltd](https://www.sectoralpha.in/stocks/swan-defence-and-heavy-industries-ltd) ₹15,047 crore · Ship - Docks/Breaking/Repairs 5. [Anupam Rasayan India Ltd](https://www.sectoralpha.in/stocks/anupam-rasayan-india-ltd) ₹15,040 crore · Speciality Chemicals ## What else do people ask about Bayer CropScience? ### What were Bayer CropScience's latest quarterly results? Bayer CropScience Ltd reported revenue of ₹1,251 Cr and net profit of ₹166 Cr for the Sep 2026 quarter. Revenue fell 19.4% and profit rose 8.5% compared with a year earlier. Earnings per share were ₹36.98. The operating margin was 17.4%, 4.2 percentage points higher than a year earlier (as of 18 November 2026). ### What is Bayer CropScience's market cap? Bayer CropScience Ltd's market capitalisation is ₹15,064 Cr at a share price of ₹3,351.80. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 18 November 2026). ### How is Bayer CropScience performing? Bayer CropScience Ltd's share price has been falling for 59 weeks. In its latest quarter, revenue fell 19.4% and profit rose 8.5% compared with a year earlier. Over the past 13 weeks it has done worse than the NIFTY 500, for 32 weeks running (as of 18 November 2026). ### Will Bayer CropScience's share price go up? This page does not forecast Bayer CropScience Ltd's share price. What it shows instead: the share price is ₹3,351.80, and it has been falling for 59 weeks. Its P/E of 20.2× is higher than 0% of its own last 10 years (as of 18 November 2026). ### Who owns Bayer CropScience? Promoters own 71.4% of Bayer CropScience Ltd, foreign institutions 4.0%, domestic institutions 11.5% and the public 13.1% (latest quarter). No group of owners changed its stake by a full point over the last two years (as of 18 November 2026). ### Does Bayer CropScience have too much debt? No, Bayer CropScience Ltd has little debt: its debt is 0.03× its equity, and its operating profit is 44 times its interest bill. FY26 borrowings were ₹82.0 Cr against equity of ₹2,966 Cr. So the returns on this page come from the business, not borrowed money (as of 18 November 2026). ### Where is Bayer CropScience in its business cycle? Bayer CropScience Ltd's FY26 operating margin was 15.4%, against a 14-year range of 4.8% to 20.1%. The latest quarter was 17.4%, near the top of its own range. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 18 November 2026). ### What could break the Bayer CropScience story? The main question: yearly earnings per share moved +21.3% while the share price moved −26.2%. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 18 November 2026). ### Is Bayer CropScience a stock worth studying right now? What the numbers show: Bayer CropScience Ltd's earnings have grown faster than its share price. Earnings per share grew +21.3% in a year while the price moved −26.2%. The main open question: whether the price catches up with earnings that have already grown. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 18 November 2026). ## Lists - Dividend stocks: https://www.sectoralpha.in/dividend-stocks-india - Small & mid cap stocks: https://www.sectoralpha.in/small-cap-stocks-india This is research, not advice. We’re not SEBI-registered.